After languishing in the doldrums for a few quarters, there are signs that the winds of investment are starting to blow again in the US digital health sector, according to market watcher Ro
One of the first actions by GSK's recently appointed chief scientific officer, Tony Wood, has been to expand a partnership with Tempus aimed at improving the big pharma's R&D productivi